[HTML][HTML] Indacaterol–glycopyrronium versus salmeterol–fluticasone for COPD
JA Wedzicha, D Banerji, KR Chapman… - … England Journal of …, 2016 - Mass Medical Soc
Background Most guidelines recommend either a long-acting beta-agonist (LABA) plus an
inhaled glucocorticoid or a long-acting muscarinic antagonist (LAMA) as the first-choice …
inhaled glucocorticoid or a long-acting muscarinic antagonist (LAMA) as the first-choice …
Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD
JA Wedzicha, D Banerji, KR Chapman… - … England Journal of …, 2016 - researchportal.vub.be
BACKGROUND: Most guidelines recommend either a long-acting beta-agonist (LABA) plus
an inhaled glucocorticoid or a long-acting muscarinic antagonist (LAMA) as the first-choice …
an inhaled glucocorticoid or a long-acting muscarinic antagonist (LAMA) as the first-choice …
[PDF][PDF] FLAME Study
JA Wedzicha - N Engl J Med, 2016 - mycs-cdn.myconferencesuite.com
* A COPD exacerbation was considered of mild severity if a worsening of symptoms that met
the symptom criteria was not treated with systemic corticosteroids and/or antibiotics; …
the symptom criteria was not treated with systemic corticosteroids and/or antibiotics; …
Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD
JA Wedzicha, D Banerji, KR Chapman… - The New England …, 2016 - research.regionh.dk
BACKGROUND: Most guidelines recommend either a long-acting beta-agonist (LABA) plus
an inhaled glucocorticoid or a long-acting muscarinic antagonist (LAMA) as the first-choice …
an inhaled glucocorticoid or a long-acting muscarinic antagonist (LAMA) as the first-choice …
[PDF][PDF] Indacaterol–Glycopyrronium versus Salmeterol–Fluticasone for COPD
JA Wedzicha, D Banerji, KR Chapman, J Vestbo… - N Engl J Med, 2016 - dickyricky.com
BACKGROUND Most guidelines recommend either a long-acting beta-agonist (LABA) plus
an inhaled glucocorticoid or a long-acting muscarinic antagonist (LAMA) as the first-choice …
an inhaled glucocorticoid or a long-acting muscarinic antagonist (LAMA) as the first-choice …
[引用][C] Indacaterol–Glycopyrronium versus Salmeterol–Fluticasone for COPD
JA Wedzicha, D Banerji, KR Chapman… - New England Journal …, 2016 - cir.nii.ac.jp
[PDF][PDF] Indacaterol–Glycopyrronium versus Salmeterol–Fluticasone for COPD
JA Wedzicha, D Banerji, KR Chapman, J Vestbo… - N Engl J …, 2016 - 81.143.226.227
BACKGROUND Most guidelines recommend either a long-acting beta-agonist (LABA) plus
an inhaled glucocorticoid or a long-acting muscarinic antagonist (LAMA) as the first-choice …
an inhaled glucocorticoid or a long-acting muscarinic antagonist (LAMA) as the first-choice …
Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD
J Wedzicha, D Banerji, K Chapman… - NEW ENGLAND …, 2016 - avesis.ankara.edu.tr
BACKGROUND Most guidelines recommend either a long-acting beta-agonist (LABA) plus
an inhaled glucocorticoid or a long-acting muscarinic antagonist (LAMA) as the first-choice …
an inhaled glucocorticoid or a long-acting muscarinic antagonist (LAMA) as the first-choice …
Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD.
JA Wedzicha, D Banerji, KR Chapman… - The New England …, 2016 - europepmc.org
Background Most guidelines recommend either a long-acting beta-agonist (LABA) plus an
inhaled glucocorticoid or a long-acting muscarinic antagonist (LAMA) as the first-choice …
inhaled glucocorticoid or a long-acting muscarinic antagonist (LAMA) as the first-choice …
[引用][C] Indacaterol/Glycopyrronium Versus Salmeterol/Fluticasone for COPD Exacerbations
JA Wedzicha, D Banerji… - The New England …, 2016 - research.manchester.ac.uk
Indacaterol/Glycopyrronium Versus Salmeterol/Fluticasone for COPD Exacerbations — Research
Explorer The University of Manchester Skip to main navigation Skip to search Skip to main …
Explorer The University of Manchester Skip to main navigation Skip to search Skip to main …